Minerva Neurosciences Inc - Asset Resilience Ratio
Minerva Neurosciences Inc (NERV) has an Asset Resilience Ratio of 48.29% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Minerva Neurosciences Inc's Asset Resilience Ratio has changed over time. Check NERV strategic asset allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Minerva Neurosciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Minerva Neurosciences Inc worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $45.41 Million | 48.29% |
| Total Liquid Assets | $45.41 Million | 48.29% |
Asset Resilience Insights
- Very High Liquidity: Minerva Neurosciences Inc maintains exceptional liquid asset reserves at 48.29% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Minerva Neurosciences Inc Industry Peers by Asset Resilience Ratio
Compare Minerva Neurosciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Minerva Neurosciences Inc (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Minerva Neurosciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.27% | $100.00K | $37.14 Million | +0.09pp |
| 2023-12-31 | 0.18% | $100.00K | $56.90 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $57.63 Million | -- |
| 2019-12-31 | 31.54% | $24.44 Million | $77.50 Million | +4.40pp |
| 2018-12-31 | 27.14% | $37.76 Million | $139.14 Million | -28.44pp |
| 2017-12-31 | 55.59% | $102.11 Million | $183.70 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $132.94 Million | -- |
| 2015-12-31 | 21.70% | $17.92 Million | $82.58 Million | +21.65pp |
| 2014-12-31 | 0.05% | $35.00K | $68.45 Million | -- |
About Minerva Neurosciences Inc
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in… Read more